Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 483

Results For "ED"

10393 News Found

Zigly launches its first pet hospital in Mumbai
News | July 18, 2025

Zigly launches its first pet hospital in Mumbai

The new Zigly center features and offers comprehensive veterinary services


Lupin receives Form 483 with 4 observations from USFDA for Pithampur unit-2
Drug Approval | July 18, 2025

Lupin receives Form 483 with 4 observations from USFDA for Pithampur unit-2

The company is addressing these observations comprehensively


Concord Biotech announces successful completion EU GMP inspection at its API facility
News | July 18, 2025

Concord Biotech announces successful completion EU GMP inspection at its API facility

This achievement underscores our unwavering commitment to upholding the highest standards of quality, safety, and regulatory compliance


Thermo Fisher Scientific to acquire Sanofi’s steriles manufacturing site in Ridgefield, New Jersey
News | July 17, 2025

Thermo Fisher Scientific to acquire Sanofi’s steriles manufacturing site in Ridgefield, New Jersey

Enables additional US manufacturing capacity to serve increased demand for pharma/biotech customers


SMS Lifesciences India receives EIR with VAI status from USFDA for API facility at Kazipally
Drug Approval | July 17, 2025

SMS Lifesciences India receives EIR with VAI status from USFDA for API facility at Kazipally

The receipt of EIR reaffirms the company's commitment to maintaining global quality standards


Cipla Health launches Astaberry's campaign 'Get the Rich Look'
News | July 17, 2025

Cipla Health launches Astaberry's campaign 'Get the Rich Look'

The campaign celebrates radiant, healthy skin that shines naturally, empowering women to step forward with confidence in every walk of life.


Waters, BD biosciences unit agree to $17.5 billion merger
News | July 16, 2025

Waters, BD biosciences unit agree to $17.5 billion merger

The transaction, approved by both companies' boards of directors, is expected to close by the end of the first quarter of 2026